Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
Conditions: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction

Interventions: Drug: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm); Drug: Fluorouracil/cisplatin (control arm)

Sponsors: Taiho Oncology, Inc.

Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 28, 2024Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments